Cargando…

The Differential Relation of Emotional, Physical, and Sexual Abuse Histories to Antidepressant Treatment Remission and Persistence of Anhedonia in Major Depression: A CAN-BIND-1 Report

OBJECTIVE: Childhood maltreatment is a potent enviromarker of risk for poor response to antidepressant medication (ADM). However, childhood maltreatment is a heterogeneous construct that includes distinct exposures that have distinct neurobiological and psychological correlates. The purpose of the c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harkness, Kate L., Chakrabarty, Trisha, Rizvi, Sakina J., Mazurka, Raegan, Quilty, Lena, Uher, Rudolf, Milev, Roumen V., Frey, Benicio N., Parikh, Sagar V., Foster, Jane A., Rotzinger, Susan, Kennedy, Sidney H., Lam, Raymond W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411366/ https://www.ncbi.nlm.nih.gov/pubmed/36785892 http://dx.doi.org/10.1177/07067437231156255

Ejemplares similares

Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication
por: Schwartzmann, Benjamin, et al.
Publicado: (2023)

Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response
por: Fiori, Laura M., et al.
Publicado: (2021)

Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1
por: Nunez, John-Jose, et al.
Publicado: (2021)

Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report
por: Caspani, Giorgia, et al.
Publicado: (2021)

Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants
por: Ju, Chelsey, et al.
Publicado: (2019)

Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy
por: Espinola, Caroline W., et al.
Publicado: (2022)

Resting-state EEG delta and alpha power predict response to cognitive behavioral therapy in depression: a Canadian biomarker integration network for depression study
por: Schwartzmann, Benjamin, et al.
Publicado: (2023)

Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 report
por: Sajjadian, Mehri, et al.
Publicado: (2023)

A standardized workflow for long-term longitudinal actigraphy data processing using one year of continuous actigraphy from the CAN-BIND Wellness Monitoring Study
por: Slyepchenko, Anastasiya, et al.
Publicado: (2023)

SNORD90 induces glutamatergic signaling following treatment with monoaminergic antidepressants
por: Lin, Rixing, et al.
Publicado: (2023)

Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study
por: Islam, Farhana, et al.
Publicado: (2022)

“One Degree of Separation”: A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19
por: Ceniti, Amanda K., et al.
Publicado: (2022)

Polish adaptation of the Dimensional Anhedonia Rating Scale (DARS) - validation in the clinical sample
por: Gorostowicz, Aleksandra, et al.
Publicado: (2023)

A Pilot Study Investigating the Effect of Music-Based Intervention on Depression and Anhedonia
por: Braun Janzen, Thenille, et al.
Publicado: (2019)

Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response
por: Marshe, Victoria S., et al.
Publicado: (2021)

Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort
por: Lam, Raymond W., et al.
Publicado: (2016)

Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report
por: Ballester, Pedro L., et al.
Publicado: (2021)

MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes
por: Lopez, Juan Pablo, et al.
Publicado: (2017)

PS110. Reversal of stress-induced anhedonia by the multimodel antidepressant, vortioxetine
por: Christensen, AK, et al.
Publicado: (2016)

Different depression: motivational anhedonia governs antidepressant efficacy in Huntington’s disease
por: McLauchlan, Duncan James, et al.
Publicado: (2022)

An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report
por: Suh, Jee Su, et al.
Publicado: (2020)

Correction to: Different depression: motivational anhedonia governs antidepressant efficacy in Huntington's disease
Publicado: (2023)

Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression
por: Zhdanov, Andrey, et al.
Publicado: (2020)

Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report
por: Harris, Jacqueline K., et al.
Publicado: (2022)

Serotonin and Dopamine Gene Variation and Theory of Mind Decoding Accuracy in Major Depression: A Preliminary Investigation
por: Zahavi, Arielle Y., et al.
Publicado: (2016)

Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report
por: Yrondi, Antoine, et al.
Publicado: (2019)

Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants
por: Hassel, Stefanie, et al.
Publicado: (2019)

Exploring brain connectivity changes in major depressive disorder using functional‐structural data fusion: A CAN‐BIND‐1 study
por: Ayyash, Sondos, et al.
Publicado: (2021)

Treatment-Resistant Depression in Primary Care Across Canada
por: Rizvi, Sakina J, et al.
Publicado: (2014)

Response of Depression to Botulinum Toxin Treatment: Agitation as a Predictor
por: Milev, Roumen
Publicado: (2015)

Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder
por: Behr, Guilherme A., et al.
Publicado: (2012)

Antidepressant-induced Remission of Gardner Diamond Syndrome
por: Sawant, Neena Sanjiv, et al.
Publicado: (2012)

Neurobiological mechanisms of anhedonia
por: Gorwood, Philip
Publicado: (2008)

Anhedonia and Depressive Disorders
por: Serretti, Alessandro
Publicado: (2023)

Towards Modeling Anhedonia and Its Treatment in Zebrafish
por: de Abreu, Murilo S, et al.
Publicado: (2021)

Rasch analyses of the Quick Inventory of Depressive Symptomatology Self-Report in neurodegenerative and major depressive disorders
por: Vaccarino, Anthony L., et al.
Publicado: (2023)

Ketamine: stimulating antidepressant treatment?
por: Malhi, Gin S., et al.
Publicado: (2016)

Anhedonia in Relation to Reward and Effort Learning in Young People with Depression Symptoms
por: Frey, Anna-Lena, et al.
Publicado: (2023)

Serotonin transporter clustering in blood lymphocytes predicts the outcome on anhedonia scores in naïve depressive patients treated with antidepressant medication
por: Rivera-Baltanas, Tania, et al.
Publicado: (2015)

The Efficacy, Safety, and Tolerability of Probiotics on Depression: Clinical Results From an Open-Label Pilot Study
por: Wallace, Caroline J. K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2s0dabddq99ugn246d7jeemcij